newsJune 17, 2026·TechCrunch AI

World model maker Odyssey nabs $1.45B valuation backed by Amazon and other big names

World models are the next big thing in AI beyond LLMs and, with this round, Odyssey has cemented itself as one of the startups to watch.

Key Takeaways

•World models are the next big thing in AI beyond LLMs and, with this round, Odyssey has cemented itself as one of the startups to watch.
•This story was reported by TechCrunch AI, covering developments in the news space.
•AI advancements continue to reshape industries — read the full article on TechCrunch AI for complete coverage.

📖 Continue reading the full article:

Read Full Article on TechCrunch AI →

Share this article

X Facebook Reddit ☕ Support

TechCrunch AI

The only AI glossary you’ll need this year

The rise of AI has brought an avalanche of new terms and slang. Here is a glossary with definitions of some of the most important words and phrases you might encounter.

The Verge AI

Anthropic wants to develop its own drugs

At the event "The Briefing: AI for Science" earlier this week, Anthropic announced Claude Science, a new "AI workbench for scientists" that pulls fragmented tools and datasets into one environment, and generates figures and visuals. Anthropic, already dominating the industry with its popular coding

The Verge AI

A behind-the-scenes look at Midjourney’s medical scanner leaves many questions unanswered

A scan of an imaging phantom, segmented to validate how cleanly structures separate under controlled conditions. | Image: Midjourney Medical Midjourney has shown more of its futuristic medical scanner. It still hasn't shown much proof it works. The AI startup, best known for generating images, re

AI News Daily

Takeda signs US$600M AI drug discovery deal with Insilico

Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas. The companies did not disclose which therapeutic areas or disease targets will be covered under the collaboratio

Discussion

Loading articles...

World model maker Odyssey nabs $1.45B valuation backed by Amazon and other big names

Key Takeaways

Related Articles

The only AI glossary you’ll need this year

Anthropic wants to develop its own drugs

A behind-the-scenes look at Midjourney’s medical scanner leaves many questions unanswered

Takeda signs US$600M AI drug discovery deal with Insilico

Discussion

World model maker Odyssey nabs $1.45B valuation backed by Amazon and other big names

Key Takeaways

Related Articles

The only AI glossary you’ll need this year

Anthropic wants to develop its own drugs

A behind-the-scenes look at Midjourney’s medical scanner leaves many questions unanswered

Takeda signs US$600M AI drug discovery deal with Insilico

Discussion

Related Articles

TechCrunch AI
The only AI glossary you’ll need this year
The rise of AI has brought an avalanche of new terms and slang. Here is a glossary with definitions of some of the most important words and phrases you might encounter.

The Verge AI
Anthropic wants to develop its own drugs
At the event "The Briefing: AI for Science" earlier this week, Anthropic announced Claude Science, a new "AI workbench for scientists" that pulls fragmented tools and datasets into one environment, and generates figures and visuals. Anthropic, already dominating the industry with its popular coding

The Verge AI
A behind-the-scenes look at Midjourney’s medical scanner leaves many questions unanswered
A scan of an imaging phantom, segmented to validate how cleanly structures separate under controlled conditions. | Image: Midjourney Medical Midjourney has shown more of its futuristic medical scanner. It still hasn't shown much proof it works. The AI startup, best known for generating images, re

AI News Daily
Takeda signs US$600M AI drug discovery deal with Insilico
Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas. The companies did not disclose which therapeutic areas or disease targets will be covered under the collaboratio